Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease
Over the past decades, monoclonal antibodies have been playing a pivotal role in the treatment of chronic inflammatory airway diseases. Currently, ample data are available on the efficacy and safety of biologics in asthma from randomized controlled trials and open-label trials; conversely, limited d...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605251340894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850262862415527936 |
|---|---|
| author | Stefania Colantuono Francesco Menzella Pier-Valerio Mari Francesco Macagno Francesco Lombardi Ilaria Baglivo Cristiano Caruso |
| author_facet | Stefania Colantuono Francesco Menzella Pier-Valerio Mari Francesco Macagno Francesco Lombardi Ilaria Baglivo Cristiano Caruso |
| author_sort | Stefania Colantuono |
| collection | DOAJ |
| description | Over the past decades, monoclonal antibodies have been playing a pivotal role in the treatment of chronic inflammatory airway diseases. Currently, ample data are available on the efficacy and safety of biologics in asthma from randomized controlled trials and open-label trials; conversely, limited data are available on the use of biologics in chronic obstructive pulmonary disease. In this context, once the fundamental role of inhaled corticosteroid/long-acting β2-agonist/long-acting muscarinic antagonist therapy is established, clinical response and disease remission, based on clinical and functional response parameters such as oral corticosteroid need, annual exacerbation rates, and lung function, are the key factors driving the clinical and therapeutic management. This narrative review has summarized the literature data from randomized controlled trials and real-life experience on currently available biologics in asthma and chronic obstructive pulmonary disease. The role of inhaled corticosteroid, long-acting β2-agonist, and long-acting muscarinic antagonist therapy has been further investigated with a particular focus on drug-free concept. |
| format | Article |
| id | doaj-art-e6f484672ffb4b99bebaa26e1228c2b4 |
| institution | OA Journals |
| issn | 1473-2300 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj-art-e6f484672ffb4b99bebaa26e1228c2b42025-08-20T01:55:06ZengSAGE PublishingJournal of International Medical Research1473-23002025-05-015310.1177/03000605251340894Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary diseaseStefania ColantuonoFrancesco MenzellaPier-Valerio MariFrancesco MacagnoFrancesco LombardiIlaria BaglivoCristiano CarusoOver the past decades, monoclonal antibodies have been playing a pivotal role in the treatment of chronic inflammatory airway diseases. Currently, ample data are available on the efficacy and safety of biologics in asthma from randomized controlled trials and open-label trials; conversely, limited data are available on the use of biologics in chronic obstructive pulmonary disease. In this context, once the fundamental role of inhaled corticosteroid/long-acting β2-agonist/long-acting muscarinic antagonist therapy is established, clinical response and disease remission, based on clinical and functional response parameters such as oral corticosteroid need, annual exacerbation rates, and lung function, are the key factors driving the clinical and therapeutic management. This narrative review has summarized the literature data from randomized controlled trials and real-life experience on currently available biologics in asthma and chronic obstructive pulmonary disease. The role of inhaled corticosteroid, long-acting β2-agonist, and long-acting muscarinic antagonist therapy has been further investigated with a particular focus on drug-free concept.https://doi.org/10.1177/03000605251340894 |
| spellingShingle | Stefania Colantuono Francesco Menzella Pier-Valerio Mari Francesco Macagno Francesco Lombardi Ilaria Baglivo Cristiano Caruso Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease Journal of International Medical Research |
| title | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease |
| title_full | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease |
| title_fullStr | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease |
| title_full_unstemmed | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease |
| title_short | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease |
| title_sort | patient response and remission in respiratory disease special focus on severe asthma and chronic obstructive pulmonary disease |
| url | https://doi.org/10.1177/03000605251340894 |
| work_keys_str_mv | AT stefaniacolantuono patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT francescomenzella patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT piervaleriomari patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT francescomacagno patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT francescolombardi patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT ilariabaglivo patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease AT cristianocaruso patientresponseandremissioninrespiratorydiseasespecialfocusonsevereasthmaandchronicobstructivepulmonarydisease |